what is glp 1 prescription GLP-1s GLP-1 Weight Loss Options |
Description
If approved for obesity in April 2026, orforglipron would initially be marketed under a single indication, with the diabetes indication expected to follow approximately 12-18 months later
The approval matters because it validates a long-sought oral small-molecule route to GLP-1 agonism, with potentially major consequences for convenience, manufacturing scale, pricing, and patent strategy
Epidemiology of inflammatory bowel disease
Trimi's 24/7 portal messaging is appropriate for managing everyday side effect questions and requesting dose adjustments
